Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Alexza partners AZ004 with Biovail; ends

Executive Summary

Alexza Pharmaceuticals (inhaled drug delivery) has licensed Biovail Laboratories International SRL exclusive US and Canadian rights to develop and sell its NDA-filed candidate AZ004 for agitation associated with schizophrenia or bipolar disorder. Biovail also has a license in the same territories for future psychiatric or neurological indications of the drug, such as symptoms associated with schizophrenia or bipolar agitation.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal

Related Companies

Advertisement
UsernamePublicRestriction

Register